The first among Indian pharmaceutical companies to realise and embrace the importance of innovation, we invest 6–8% of global revenues annually into Research and Development (R&D). With a team of over 2,900 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, our strength lies in developing generics and technologically complex products. We specialize in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing our strong focus on innovation.
Recent Posts
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
- Sun Pharma reports Q3FY26 results
- Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
Recent Comments